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   DETERMINATION OF PRILOCAINE HCl IN 
BULK DRUG AND PHARMACEUTICAL 
FORMULATION BY GC-NPD METHOD 
A novel analytical method was developed and validated for determination of 
prilocaine HCl in bulk drug and pharmaceutical formulation by gas chroma-
tography-nitrogen phosphorus detection (GC-NPD). The chromatographic 
separation was performed using a HP-5MS column. The calibration curve was 
linear over the concentration range of 40-1000 ng ml
-1 with a correlation coef-
ficient of 0.9998. The limits of detection (LOD) and quantification (LOQ) of the 
method were 10 and
 35 ng ml
-1, respectively. The within-day and between-day 
precision, expressed as the percent relative standard deviation (RSD%) were 
less than 5.0%, and the accuracy (percent relative error) was better than 4.0%. 
The developed method can be directly and easily applied for determination of 
prilocaine HCl in bulk drug and pharmaceutical formulation using internal 
standard methodology. 
Keywords: GC-NPD, prilocaine HCl, pharmaceutical formulation, vali-
dation. 
 
 
Local anesthetic drugs are mainly used to 
reversibly block nerve function in various local or regi-
onal treatments. They play an important role clinically 
in dentistry and minor surgery for temporary relief of 
pain [1,2]. Prilocaine, 2-propylamino-N-o-tolil-propi-
yonamit hydrochloride (Figure 1A), is a local anes-
thetic of the amide type [3]. Prilocaine, unlike other 
amide anesthetics, is a secondary amino derivative of 
toludine. It produces less vasodilation and toxicity 
than lidocaine and is considered relatively free from 
an allergic reaction [4]. Prilocaine is extensively meta-
bolized by the liver. Prilocaine’s primary limiting factor 
clinically is the production of methemoglobinemia, a 
side effect caused by its metabolite o-toludine [5,6].  
Several methods have been reported for deter-
mination of prilocaine HCl in biological samples and 
pharmaceutical formulations including the capillary 
electrophoresis method [3], HPLC with different de-
tection [5,6-16], liquid chromatography-tandem mass 
spectrometry [17], sequential injection chromato-
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graphy with Franz cell [18], adsorptive square wave 
method [19] and spectrophotometry method [20]. In 
addition, the determination of mixtures with other local 
anesthetics of prilocaine HCl in biological samples 
have been done with GC-MS [21,22] and GC me-
thods [23-29]. 
 
Figure 1. Chemical structure of: A) prilocaine HCl; 
B) IS (lidocaine HCl). 
So far, according to our present knowledge, no 
GC-NPD method for the analysis of prilocaine HCl 
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in the literature. The development a selective and 
effective method for drug analysis is important for 
keeping abreast of therapeutic and toxic effects in 
biological samples and quality controlling studies in 
pharmaceutical formulations. The aim of the present 
work is to develop and validate a new GC-NPD me-
thod for determination of prilocaine HCl in pharma-
ceutical formulation with a simple sample preparation 
using internal standard methodology. The proposed 
method was validated with validation parameters, 
which are sensitivity, specificity, linearity, precision, 
accuracy, stability and analytical recovery in accor-
dance with International Conference on Harmoniza-
tion (ICH) guidelines [30].
 
EXPERIMENTAL 
Materials and reagents 
Prilocaine HCl, which was used as the reference 
substance (99.9% purity), was supplied by Novartis 
Pharmaceutical Industry (Ankara, Turkey). Lidocaine 
HCl (99.8% purity), which was used as the internal 
standard (IS; Figure 1B), was supplied by the Doping 
Control Center of Hacettepe University (Ankara, Tur-
key). High-purity grade methanol and all other rea-
gents were purchased from Merck (Germany). All 
gases were supplied by Havas (Ankara, Turkey). 
The following pharmaceutical formulation of pri-
locaine HCl was obtained from local sources in Erzu-
rum (Turkey): Citanest
® injection (2% flacon, Astra 
Zeneca A.S., Turkey) containing prilocaine HCl, para-
hydroxybenzoate and sodium chloride with the con-
centration of 20, 1 and 0.46 mg ml
-1, respectively. 
Equipment 
The chromatographic analysis was performed 
by an HP 6890 Series II gas chromatography system 
equipped with an HP 7673 auto sampler, HP auto-
matic injector (Model 7673), HP 5890 nitrogen-phos-
phorus detector (NPD) and HP software.  
Chromatographic conditions 
Chromatographic separation was achieved using 
an HP-5MS column (25 m×0.2 mm i.d.×0.33 μm film 
thickness, cross-linked [% phenyl-methylpolysiloxano, 
Germany). The split mode (10:1) was used and the 
flow rate of the carrier gas (helium) was kept constant 
at 0.7 ml min
-1 during the analysis. Hydrogen (4 ml 
min
-1) and dried air (60 ml min
-1) were used as aux-
iliary gases for the detector (NPD). The injector 
volume was 3.0 μl. The injector and detector tempe-
ratures were 250 °C. The oven temperature programs 
were as follows: initial temperature of 80 °C, then 
ramp rate of 15 °C min
-1 and final temperature of 300 
°C, where the temperature was held for 4 min. The 
chromatograms obtained in these operating condi-
tions for standard solutions, are shown in Figure 2. 
Preparation of standard solutions  
The standard working (SW) solutions (40, 100, 
250, 500, 750 and 1000 ng ml
-1) and quality control 
(QC) samples (100, 250 and 500 ng ml
−1) were pre-
pared in methanol from stock solution (100 µg ml
-1). 
All solutions were prepared daily and stored at -20 °C 
when not in use. 
SW solution of lidocaine HCl (internal standard, 
IS) was prepared at 100 ng ml
-1 concentration with 
methanol from the stock solution (50 µg ml
-1).  
Preparations of pharmaceutical formulation 
Prilocaine (Citanest
® flacon) is a drug that is 
injected during various surgical or dental procedures. 
The content of a flacon was mixed into a volumetric 
flask and an aliquot of the solution equivalent to 20 
mg prilocaine HCl was quantitatively transferred to a 
 
Figure 2. GC-NPD Chromatogram of standard solutions (40, 100, 250, 500, 750 and 1000 ng ml
-1) of prilocaine and IS (100 ng ml
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50 ml calibrated measuring flask and made up to the 
mark with methanol. The solution was filtered through 
a 0.22 µm Millipore filter. The filtrate was diluted with 
methanol to obtain a 150 ng ml
-1 concentration of pri-
locaine HCl for pharmaceutical formulation. 
About 100 ng ml
-1 concentration of IS was 
added into the solution prepared from the flacon. The 
solution was analyzed as described in the section 
Chromatographic conditions.  
Data analysis  
All statistical calculations were performed with 
the Statistical Product and Service Solutions (IBM 
SPSS) for Windows, version 20.0. Correlations were 
considered statistically significant if the calculated P 
values were 0.05 or less. 
RESULTS 
Specificity 
Specificity should confirm the ability of the 
method to unequivocally assess the analyte in the 
presence of other components that may be present 
(for example: impurities, degradation products and 
matrix components). The specificity of method was 
demonstrated by the representative chromatograms 
for prilocaine HCl and lidocaine HCl (IS) in standard 
solutions shown in Figure 2. The retention time of 
prilocaine HCl and lidocaine HCl was 6.78 min and 
7.22 min. Different temperature programs were inves-
tigated for the exception of matrix interference. At the 
end of this investigation, the best temperature pro-
gram was selected for a good resolution and thus the 
all experiments was used the oven temperature pro-
gram described at section Chromatographic condi-
tions. When the ramp rate was more or less than 15 
°C min
-1, good resolution of the peaks (analyte peak 
and matrix interference peaks) was not obtained.  
Linearity 
Linearity was established over a linear range of 
40–1000 ng ml
-1 at six concentrations with a constant 
concentration of IS (100 ng ml
-1). The calibration curve 
was constructed by plotting the ratio of the peak areas 
of prilocaine HCl and IS, versus the concentrations of 
prilocaine HCl (Figure 3). The linear regression equa-
tion and statistical parameters were calculated by the 
least squares method using Microsoft Excel
® and 
summarized in Table 1. Relative residual standard 
deviation (S∆y/y,n-2) is also included in the table [31]. 
Limit of detection and quantification 
The limit of detection (LOD) is the lowest 
amount of analyte in a sample that can be detected, 
but not necessarily quantitated as an exact value. The 
limit of quantification (LOQ) is the lowest amount of 
analyte that can be quantitatively determined with 
suitable precision [30]. The LOD and LOQ values of 
the developed method were determined as 3:1 and 
10:1 of the signal/noise ratio, respectively, by injecting 
progressively low concentration of the standard 
solution under the chromatographic conditions. These 
values are also listed in Table 1. 
 
Figure 3. Calibration curve for determination of prilocaine HCl 
with proposed method. 
Table 1. Results of regression analysis of prilocaine HCl 
Parameter  GC-NPD 
Linearity, ng ml
-1  40-1000 
Regression equation
a  y = 0.0073x-0.0484
b 
Standard deviation of slope (Sa) 5.4×10
-4 
Standard deviation of intercept (Sb) 2.8×10
-2 
Correlation coefficient  0.9998 
Standard deviation of correlation coefficient  0.0045 
Relative residual standard deviation (S∆y/y, n-2) 0.059 
Limit of detection (LOD), ng ml
-1 10 
Limit of quantification (LOQ), ng ml
-1 35 
aAverage of six replicate determinations; 
by: peak-area ratios (prilocaine/IS), x: prilocaine concentration A. ATILA, Y. KADIOGLU: DETERMINATION OF PRILOCAINE HCl…  CI&CEQ 19 (2) 313−319 (2013) 
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Precision and accuracy 
Assay precision was determined by repeatability 
(within-day) and intermediate precision (between-
day). The within-day was evaluated by assaying 
samples, at same concentration and during the same 
day. The between-day was studied by comparing the 
assay on different six days. The accuracy of this anal-
ytic method was evaluated by checking at three diffe-
rent concentrations of prilocaine HCl with IS. The pre-
cision of method was given as the relative standard 
deviation [RSD % = (100×standard deviation)/mean] 
and the accuracy of method was given with percent 
relative error [RE% = (found concentration – known 
concentration)×100/known concentration]. The RSD % 
values for within-day and between-day precision of 
proposed method were found to be ≤4.9%. The RE% 
for within-day and between-day accuracy for method 
were found to be ≤3.8%. Precision and accuracy stu-
dies in pharmaceutical formulation showed accep-
table RSD % and RE % values. The results are shown 
in Table 2. 
Analytical recovery 
In order to double-check the accuracy of the 
proposed method, the recovery study was performed 
in two different ways. In first method, the standard 
addition technique was used. The three different con-
centrations (100, 250 and 500 ng ml
-1) of standard 
sample were added to 150 ng ml
-1 concentration of 
solution of pharmaceutical formulation and assayed 
with GC-NPD method. The analytical recovery values 
of proposed method were calculated from followed 
equation:  
Analytical recovery, % = 100[(Ct-Cu)/Ca] 
where Ct is total concentration of the analyte deter-
mined; Cu is the concentration of the pure analyte 
added to the formulation; Ca is the concentration of the 
analyte present in the formulation. The average per-
cent recoveries were determined between 98.6 and 
99.6% for proposed method, indicating good accuracy 
of the method. No interference from the common exci-
pients was observed. The RSD % values of recovery 
were found to range from 0.9 to 1.4% (Table 3). 
In the second method, the technique of propor-
tioning was used. The solutions in three different con-
centrations (100, 250 and 500 ng ml
-1) from pharma-
ceutical formulation were prepared and assessed with 
same procedures. The percent recovery values were 
calculated from followed equation for each case: 
Recovery % = 100(Cfound/Cformulation). The average reco-
very values for second method were determined 
between from 100.1 and 98.8%. The RSD % values 
of recovery were found to range from 1.9 to 1.2% 
(Table 3). 
The recovery values of both methods were com-
pared statistically by the One-Sample t-test at 95% 
confidence level with five degrees of freedom. The 
t-values were obtained as t  = 529.2 for the first 
method and t = 415.5 for the second method. There 
was no significant difference between both recovery 
methods (p > 0.05). 
Interferences study 
The effects of common excipients and additives 
were tested for their possible interferences in the 
assay of prilocaine HCl. In addition to the active in-
gredient, prilocaine HCl, flacon contains the following 
inactive ingredients: methyl para-hydroxybenzoate 
and sodium chloride. No interference of these sub-
stances at the levels found was determined in dosage 
forms. 
Stability  
Stability studies were performed on pharmaceu-
tical formulation and standard solutions of prilocaine 
HCl (250, 500 and 750 ng ml
-1) and these solutions 
were stored at 4 °C (refrigerator), room temperature 
and auto sampler at 24, 48 and 72 h time and then 
changes in concentration of standard solutions and 
pharmaceutical formulation under conditions of the 
study were evaluated using the GC-NPD method. 
One set of these solutions was assayed immediately 
and taken as the standard (100%). The stock solution 
of prilocaine HCl was found to be stable for three 
month. Standard solutions of prilocaine HCl and phar-
maceutical solution were found to be stable for 48 h at 
room temperature and on auto sampler. After 72 h at 
Table 2. Precision and accuracy of GC-NPD method 
Added 
ng ml
-1 
Within-day Between-day 
Found±SD
a 
ng ml
-1 
Precision
b 
RSD, % 
Accuracy
c 
RE, %
 
Found±SD
a 
ng ml
-1 
Precision
b 
RSD, % 
Accuracy
c 
RE, %
 
100 103.3±2.7  2.6  3.3  101.1±5.0 4.9  1.1 
250 251.9±2.6 1.0  0.8  250.8±8.6 3.4  0.3 
500 480.9±9.5 2.0  -3.8  495.7±8.9  1.8  -0.9 
aSD: standard deviation of six replicate determinations, 
bRSD: relative standard deviation, 
cRE: relative error A. ATILA, Y. KADIOGLU: DETERMINATION OF PRILOCAINE HCl…  CI&CEQ 19 (2) 313−319 (2013) 
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room temperature and auto sampler, it was observed 
that prilocaine converted to its metabolite (o-toluidine) 
(Figure 4). Because of its chemical structure, prilo-
caine is readily hydrolyzed in alcohol medium.  The 
formation of o-toluidine as a major degradation pro-
duct in solutions of prilocaine HCl was checked by 
spiking of the standard solution of o-toluidine. o-Tolu-
idine could be formed during degradation of prilocaine 
HCl, based on the information in the literature that 
amide anesthetics were degraded to o-toluidine with 
temperature change [5,14]. 
Application of method for analysis of pharmaceutical 
formulation 
The proposed method was evaluated in the assay 
of commercially available flacon containing prilocaine 
HCl 400 mg/20 ml (Citanest
® flacon). Evaluation was 
performed using the calibration curve method, since 
no significant difference between the slopes of the 
calibration curves for pharmaceutical formulation and 
standard solutions was observed. The amount of fla-
con containing 400 mg prilocaine HCl per 20 mL was 
determined in six replicates. The results obtained are 
satisfactorily accurate and precise as indicated by the 
excellent % recovery and SD < 4.25 (Table 4). The 
experiments showed that there was no interference 
from the additions and excipients. The determination 
was repeated six times, and the final obtained 
recovery of the formulation was approximately 98.9%, 
with an RSD % of 1.07. 
Table 4. Determination of prilocaine HCl in flacon (400 mg prilo-
caine HCl/20 ml) 
Pharmaceutical 
formulation 
Found±SD
a 
mg 
Recovery 
% 
RSD
 
% 
Confidence 
interval 
Citanest
® inject-
tion (2% flacon) 
395.6±4.25 98.9  1.07  98.0-99.9
aAverage of six replicate determinations 
DISCUSSION 
In the present study, a highly selective gas chro-
matography (GC) with nitrogen-phosphorous detec-
tion (NPD) that enabled us to quantify the prilocaine 
HCl without derivatization in pharmaceutical formu-
lation was developed and validated. Prilocaine HCl is 
one of local anesthetic substances. Chromatographic 
Table 3. Analytical recovery values with two ways of performing the proposed method 
Technique 
Amount added  
ng ml
-1 
Amount taken
a 
ng ml
-1 
Total amount found, mean±SD 
ng ml
-1 
Recovery 
% 
RSD 
% 
The standard addition technique  100  150  248.9±2.8  99.3  1.1 
250 397.9±5.7  98.6  1.4 
500 649.4±6.1  99.6  0.9 
The technique of proportioning  -  100  98.8±1.9  98.8  1.9 
250 250.2±4.4  100.1  1.8 
500 497.8±5.8  99.6  1.2 
aSolutions of pharmaceutical preparation, 
baverage of six replicate determinations 
 
Figure 4. GC Chromatogram of prilocaine and o-toluidine formed during storage at auto sampler during 72 h period. A. ATILA, Y. KADIOGLU: DETERMINATION OF PRILOCAINE HCl…  CI&CEQ 19 (2) 313−319 (2013) 
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analyses of pharmaceutical compounds have evolved 
as drug industry matured. Gas-liquid chromatography 
(GLC) developed in the early 1950s to the present 
with many concurrent innovations in chromatography 
columns and detection systems [32]. Gas chromato-
graphy has found its niche in the monitoring of certain 
impurities, measuring and characterizing excipients, 
preservatives, and active drugs. In assays where sen-
sitivity is required, gas chromatographic methods are 
still unsurpassed [32]. An important aspect of the 
implementing a new assay in routine quality control 
analysis is that it should be thoroughly evaluated 
before introduction for routine use. GC with different 
detections can be considered a very appropriate 
method for analysis of local anesthetic substances 
that these are very volatile substances. The proposed 
method has supplied all the requirements in terms of 
accuracy, linearity, recovery and precision that could 
be accepted as a reliable and applicable method. The 
precision of method was adequate, because the RSD 
values were less than 5.0%. The accuracy of method 
(RE) was less than 4.0%. There are several advanta-
ges of this method, namely high specificity, good 
accuracy and precision values, short chromatographic 
run time (7.5 min). In the chromatograms taken with 
proposed method, the following peaks: prilocaine HCl 
with retention time approximately 6.78 min; lidocaine 
HCl (IS) with retention time approximately 7.22 min 
and the degradation product o-toluidine with retention 
time of approximately 2.15 min (Figures 2 and 4), 
were identified. Under the described chromatographic 
conditions (Figure 3), a linear relationship between 
the peak-area ratio (y = prilocaine peak area/IS peak 
area) and analyte (prilocaine) concentration (x) were 
obtained (Table 1). In addition to these, the analytical 
recovery percentage of proposed method is high. 
There are many preparations for local anes-
thesia on the pharmaceutical market, in which prilo-
caine and lidocaine can occur as active substances. 
Both drugs were served as the internal standard for 
each other. Prilocaine used in anesthetic practice is 
less toxic than lidocaine. o-Toluidine is a metabolite of 
prilocaine. Prilocaine metabolizes to o-toluidine during 
biotransformation, which many oxidize hemoglobin to 
methemoglobin and also o-toluidine has been shown 
to be carcinogenic in laboratory animals in the Nati-
onal Toxicology Program (NTP) studies [33]. o-Tolu-
idine can be potential technological impurities of 
medicinal products because they are used as sub-
strates in the synthesis of pharmaceuticals. In addi-
tion, the hydrolysis of the amide linkage of prilocaine 
results in the formation of decomposition product 
o-toluidine during storage of drugs containing prilo-
caine [5,14,33]. After 72 h storage of standard solu-
tions of prilocaine and pharmaceutical formulation, it 
was observed that prilocaine was converted to its 
metabolite (o-toluidine). The content of o-toluidine in 
standard solutions and pharmaceutical formulation 
chosen for this study was determined by the standard 
addition method, while the content of local anes-
thetics in pharmaceutical formulation studied was 
assayed by GC-NPD method. 
CONCLUSION 
In this study, a new GC-NPD method was deve-
loped to provide a very sensitive and quantitative assay 
of prilocaine HCl in bulk drug and pharmaceutical 
formulation. In addition, o-toluidine was determined in 
stability studies. The analysis and preparation of 
samples was performed in a relatively short time. The 
method can be applied in routine quality control anal-
ysis of pharmaceutical formulations and clinical labo-
ratories. 
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NAUČNI RAD 
   ODREĐIVANJE PRILOKAIN HIDROHLORIDA U 
FARMACEUTSKOJ SUPSTANCI I PREPARATIMA 
METODOM GC-NPD 
Razvijena je i validirana nova metoda za određivanje prilokain-hidrohlorida u farma-
ceutskoj supstanci i preparatima metodom GC-NPD. Hromatografsko razdvajanje je 
izvršeno kolonom HP-5MS. Kalibraciona kriva je bila linearna u opsegu koncentracije 
40-1000 ng/ml, sa koeficijentom korelacije 0,9998. Limit detekcije (LOD) i limit kvanti-
fikacije (LOQ) ove metode su bili10 i
 35 ng/ml, redom. Preciznost metode u toku dana i 
različitim danima, izražena kao procentna relativna standardna devijacija, bila je manja 
od 5%, dok je tačnost metode (procentna relativna greška) bila manja od 4%. Razvijena 
metoda se može direktno i lako primeniti za određivanje prilokain-hidrohlorida u farma-
ceutskoj supstanci i preparatima koristeći internu standardnu metodologiju. 
Ključne reči: GC-NPD, prilokain-hidrohlorid, farmaceutski preparati, validacija. 
 
 